Prima Donna

DONNA

Oral health

Introducing Project Prima Donna: the first-ever treatment designed to regenerate lost enamel to keep you smiling for a lifetime. Enamel erosion is an irreversible, age-related condition that no one is immune from, leading to tooth sensitivity, cavities, and more severe health complications. Current solutions, such as fluoride rinses, crowns, or veneers, merely mask the problem without addressing the root cause. Spearheaded by renowned stem cell researchers and dentists Dr. Hannele Ruohola-Baker, Dr. Julie Mathieu, and Dr. Jonathan An, this project utilizes breakthroughs in induced pluripotent stem cell (iPSC) technology to develop enamel-regenerating organoids. These organoids have shown promising results in the lab and are now ready for testing in a relevant animal model. This is an important step towards developing a drug that can move us beyond mere symptom management, to restore our natural ability to produce enamel. The global economic burden of poor oral health was estimated to be $544 billion in 2015, and oral health is the most prevalent non-transmissible disease worldwide. If successful, this treatment stands to significantly reduce the global burden of dental diseases and healthcare costs. Join us on our journey to revolutionize oral health and to create a future where aging never dims your brilliant smile.

Owned by

0x27EFA…a6BB6

Contract:

0x61527…2a8d0

Description

Spearheaded by renowned stem cell researchers and dentists Dr. Hannele Ruohola-Baker, Dr. Julie Mathieu, and Dr. Jonathan An, this project utilizes breakthroughs in induced pluripotent stem cell (iPSC) technology to develop enamel-regenerating organoids. These organoids have shown promising results in the lab and are now ready for testing in a relevant animal model. This is an important step towards developing a drug that can move us beyond mere symptom management, to restore our natural ability to produce enamel.

The global economic burden of poor oral health was estimated to be $544 billion in 2015, and oral health is the most prevalent non-transmissible disease worldwide. If successful, this treatment stands to significantly reduce the global burden of dental diseases and healthcare costs. Join us on our journey to revolutionize oral health and to create a future where aging never dims your brilliant smile.

Team

Dr Hannele Ruohola-Baker

Research Lead

Organisation

University of Washington

Experiment Cost

$253,541.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

The project has demonstrated early proof-of-concept efficacy in an in vivo animal model. Specifically, Notch-activated iPSC-derived ameloblast organoids transplanted under the kidney capsule of NOD-SCID mice generated enamel-like calcified material confirmed by microCT imaging, while control organoids did not produce this effect. This represents functional validation in a living system with measurable, disease-relevant outcomes (calcified tissue formation), meeting the criteria for TRL 3.

Assessment

High Confidence

RecommendationSUPPLEMENT

Total Score3.00

Overall Assessment

PrimaDonna scores 3.0/5.0, indicating moderate overall potential at TRL 2-3 transition. Key strengths include compelling therapeutic relevance addressing massive unmet need in enamel regeneration, initial in vivo proof-of-concept, strong academic team, and foundational IP protection. The AI-designed Notch ligand approach is innovative. However, significant gaps exist in safety characterization, regulatory planning, manufacturing scale-up, and candidate optimization. The project demonstrates promising biological foundation but requires substantial de-risking before advancing to IND-enabling studies. Priority actions should include: (1) safety/toxicology assessment framework, (2) cryopreservation validation and dose-finding studies, (3) regulatory strategy development, and (4) scale-up to achieve target cell numbers for robust preclinical studies.

Weighted Score

Price of DONNA

$0.0151

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$DONNA	USD	ETH	From

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

Assessment

High Confidence

RecommendationSUPPLEMENT

Total Score3.00

Overall Assessment

Weighted Score

Therapeutic Relevance

Strong therapeutic relevance with clear mechanism targeting enamel regeneration via iPSC-derived ameloblast organoids expressing key enamel matrix proteins (AMELX, AMBN, ENAM). In vivo proof-of-concept achieved with enamel-like calcified material formation in mouse model. Addresses massive unmet need (2.4B affected by dental caries, $120B US market). Deducted for being early-stage with limited quantitative efficacy data.

Therapeutic Optionality

Platform has potential expansion into amelogenesis imperfecta (validated DLX3 KO disease model) and potentially other genetic enamel disorders. Drug discovery engine concept suggests broader applications, but currently focused primarily on enamel regeneration without clear evidence of multi-indication development strategy.

Intellectual Property

PCT patent application filed (PCT/US2022/053517) with Dec 2021 priority date covering iPSC-derived ameloblasts and uses. Strong inventor list including David Baker. However, scope of IP protection and freedom-to-operate assessment not specified, and competitive landscape analysis absent. Patent protection appears foundational but completeness of strategy unclear.

Utility Of Candidates

Organoids demonstrate functional enamel matrix protein expression and initial in vivo activity (enamel-like calcified material in kidney capsule model). AI-designed Notch ligand improves maturation. However, minimum effective cell number not determined, cryopreservation not validated, and no dose-response or optimization data provided. Candidates show promise but lack characterization depth expected at TRL 3.

Prospects For Safety

Safety data section explicitly marked as blank/not specified. NOD-SCID mouse transplantation provides minimal safety signal (immunodeficient model). No in vitro safety screening, GLP toxicology, or systematic safety assessment reported. Cell therapy products carry inherent risks (tumorigenicity, immunogenicity) that require extensive characterization not yet begun.

Prospects For Gmp Cmc

QC framework established with viability, identity, and functional metrics. Protocols standardized with trained personnel. However, full scale-up not achieved, manufacturing route not specified, and cryopreservation validation incomplete. Cell therapy manufacturing complexity acknowledged but GMP pathway and challenges not addressed.

Prospects For Clinical Development

Regulatory pathway explicitly listed as not specified. Clinical endpoint strategy unknown. No discussion of FDA pathway (likely biologics/CBER), clinical trial design, or patient selection. Long path to human application for iPSC-derived cell therapy with many regulatory hurdles not yet addressed.

Commercial Potential

Addresses large market (>$120B US dental care, 2.4B affected globally). Clear unmet need with no current biological enamel regeneration options. Platform positioned for both therapeutic products and drug discovery engine. Market validation strong, though competitive landscape and pricing strategy not discussed.

Organization And Team Fit

Strong academic team including Profs. Hannele Ruohola-Baker, Julie Mathieu, Jonathan An with expertise in stem cell biology. David Baker involvement brings AI protein design credibility. Personnel trained and protocols standardized. Some gaps in team information but core competencies appear solid for current stage.